Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Follow-Up Questions
Who is the CEO of Adial Pharmaceuticals Inc?
Mr. Cary Claiborne is the President of Adial Pharmaceuticals Inc, joining the firm since 2021.
What is the price performance of ADIL stock?
The current price of ADIL is $0.3504, it has decreased 2.08% in the last trading day.
What are the primary business themes or industries for Adial Pharmaceuticals Inc?
Adial Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Adial Pharmaceuticals Inc market cap?
Adial Pharmaceuticals Inc's current market cap is $7.6M
Is Adial Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Adial Pharmaceuticals Inc, including 2 strong buy, 5 buy, 2 hold, 0 sell, and 2 strong sell
